Bernard Coulie sold $587k of PLRX
President and CEO at PLIANT THERAPEUTICS, INC.. 52,419 shares at an average of $11.20, traded Jan 17, 2025, filed Jan 22, 2025.
Score components
- +25RoleCEO
- +19Trade size$587k at market
- +5Share of holdings soldSold 11% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001746473-25-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | SOpen-market sale Common Stock10b5-1 | -52,419 | $11.20 | $587k | 430,517 | Jan 22, 2025 |
Related signals
Other insiders at PLIANT THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | PLIANT THERAPEUTICS, INC. | Lily Cheung Chief Human Resource Officer | $42k 3,740 shares | -13% | |
| 30Weak | PLIANT THERAPEUTICS, INC. | Keith Lamont Cummings Chief Financial Officer | $226k 20,148 shares | -7% | |
| 22Weak | PLIANT THERAPEUTICS, INC. | Hans Hull Chief Business Officer | $179k 15,936 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.